Friday, 15 Nov 2019

You are here

Prior Cancer Patients May Safely Receive TNF Inhibitors or Rituximab

Current guidelines regarding the use of biologics in patients who have previously had a malignancy are based more on opinion than evidence.

The ARTIS registry previously showed that women with a prior breast cancer who went on to receive a TNF inhibitor (TNFi) were not at great risk of breast cancer recurrence ( They have also showed that cancers occurring after initiation of TNFi therapy do not have worse outcomes or reduced survival compared to cancer patients not exposed to TNFi (

The British Biologics Registry (BSRBR) examined 425 patients with a prior malignancy and assessed rates of recurrent malignancy in  patients treaed with either a TNFi, rituximab (RTX) or synthetic DMARDs (sDMARD).

Roughly one-quarter developed a new malignancy. The incident malignancy rates and adjusted hazard ratios (HR) were:

 Cancer Recurrence TNFiRTXsDMARD

Recurrent Malignancy Rate/1000OPY

Hazard Ratio0.550.43-
(95% CI) (0.35, 0.86)(0.10, 1.80-


The 17.0% of patients in the sDMARDs cohort had a recurrence of the same cancer in comparison with the 12.8% and the 4.3% in the TNFi and RTX cohorts.

These findings suggest that RA patients with a prior malignancy may be safetly treated with either a TNFi or RTX.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Frequent DMARD Discontinuations During Rheumatoid Pregnancies

A Canadian population-based study shows that pregnant women with rheumatoid arthritis (RA) frequently discontinue their DMARD medications, especially in the first trimester.

An administrative data study looked at women with RA with a singleton pregnancy who were studied for utilization of RA medications, including conventional synthetic DMARDs, biologics, glucocorticosteroids and NSAIDs.

Methotrexate and the Risk of Lung Disease

Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.

Common Physician HIPAA Violations

A nice review by Physician Sense and MDLinx discusses potential physician violations of current HIPAA law, largely driven by the digital age and common work flows. Several mistakes you you be aware of and avoid, include:

Forwarding PHI to a personal email account

FDA Issues Boxed Warning and Recommendations for Breast Implant Use

The U.S. Food and Drug Administration has issued a new draft guidance document calling for a boxed warning and delineation of risks with breast implants.

Voluntary Recall of Zantac by Sanofi/FDA

Sanofi has initiated a voluntary recall of all Zantac OTC (over-the-counter) products in the United States. This includes Zantac 150®, Zantac 150® Cool Mint, and Zantac 75®. Zantac tablets are an oral, over-the-counter product to prevent and relieve heartburn associated with acid ingestion and sour stomach.